Rituxan (rituximab) - Roche
Clinicopathologic Features and Kidney Outcomes in Primary Antiphospholipid Syndrome-Associated Nephropathy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0842; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Rituximab-based regimens were used in 63.6% of cases, while complement inhibition was reserved for severe or refractory disease in 18.2%...Conclusion Primary APS-associated nephropathy is predominantly characterized by chronic microvascular and endothelial injury patterns with frequent chronic TMA-related lesions. Despite heterogeneous presentations, most patients achieved renal stabilization under multimodal therapy, although persistent chronic kidney disease burden remained substantial." 
Clinical • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Genetic Disorders • Glomerulonephritis • Hematological Disorders • Hypertension • Nephrology • Renal Disease
https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4557674
 
Irina Lucia Bercaru; Alexandru Radu Iercosan; Stefan Nicolaie Lujinschi; Gener Ismail
 
Oct 2, 2026
 
Prev Next